{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T07:49:03Z","timestamp":1773474543184,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1395,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Helicobacter"],"published-print":{"date-parts":[[1998,3]]},"abstract":"<jats:sec><jats:title>Background.<\/jats:title><jats:p>Multiple regimens for the eradication of <jats:italic>Helicobacter pylori<\/jats:italic> have been tested, but the best therapy has not been determined yet. To determine the efficacy of a new triple agent regimen using a combination of lansoprazole, amoxicillin, and clarithromycin against <jats:italic>Helicobacter pylori<\/jats:italic> (<jats:italic>H. pylori<\/jats:italic>), and to examine <jats:italic>H. pylori<\/jats:italic> resistance to this therapy in ineffective cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We studied a total of 71 patients infected with <jats:italic>H. pylori<\/jats:italic> who had gastric ulcer (<jats:italic>n<\/jats:italic>~=~37) or duodenal ulcer (<jats:italic>n<\/jats:italic>~=~34) as confirmed by endoscopy. Patients received 1500~mg amoxicillin, 400~mg clarithromycin and 30~mg lansoprazole for 2~weeks followed by 30~mg lansoprazole for 6~weeks in patients with gastric ulcer or for 4~weeks in those with duodenal ulcer. Endoscopic examination was performed before treatment and at 1~month, 2~months, and 5~months after initiating treatment to check the status of ulceration and <jats:italic>H. pylori<\/jats:italic> infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>The eradication rate of <jats:italic>H. pylori<\/jats:italic> was 92% (CI, 83\u2013100%) in the gastric ulcer group and 94% (CI, 86\u2013100%) in the duodenal ulcer group at 5~months, as determined by per\u2010protocol analysis. Resistance to clarithromycin was present in 1 of 71 (1%) patients before treatment and in 2 of 5 (40%) patients after treatment. No resistance to amoxicillin and lansoprazole was found in patients before or after treatment. The resistance to clarithromycin changed during the observation period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions.<\/jats:title><jats:p>The new triple agent regimen was effective against <jats:italic>H. pylori<\/jats:italic>. Resistance to clarithromycin may not be permanent and it might be one of the risk factors which affect the efficacy of a clarithromycin\u2010based therapy.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1523-5378.1998.08021.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T23:20:28Z","timestamp":1047424828000},"page":"59-63","source":"Crossref","is-referenced-by-count":22,"title":["Assessment of a New Triple Agent Regimen for the Eradication of <i>Helicobacter pylori<\/i> and the Nature of <i>H. pylori<\/i> Resistance to This Therapy in Japan"],"prefix":"10.1111","volume":"3","author":[{"given":"Junko","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Mine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Intetsu","family":"Kobayasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-9-705"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199501193320302"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)93145-F"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.3.490"},{"issue":"4","key":"e_1_2_5_6_2","first-page":"A203","article-title":"Evidence of Helicobacter pylori resistance to antibiotics in non\u2013eradicated cases treated with new triple therapy","volume":"110","author":"Murakami K","year":"1996","journal-title":"Gastroenterol"},{"key":"e_1_2_5_7_1","unstructured":"Jerris RC. Helicobacter. In: Murray PR ed. Manual of Clinical Microbiology 6th ed. Washington DC: American Society for Microbiology 1995: 492\u20138."},{"key":"e_1_2_5_8_2","first-page":"1552","article-title":"The who's and when's of therapy for Helicobacter pylori","volume":"85","author":"Graham DY","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.9.1650"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.5.1133"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03520010077036"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.9.1167"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529409091407"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90502-T"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199506002-00020"},{"issue":"4","key":"e_1_2_5_16_2","first-page":"A171","article-title":"Triple therapy with PPI\u2010amoxicillin\u2010clarithromycin for Helicobacter pylori eradication: the optimal regimen in 1996","volume":"110","author":"Lamouliatte H","year":"1996","journal-title":"Gastroenterol"},{"issue":"4","key":"e_1_2_5_17_2","first-page":"A198","article-title":"One week low\u2010dose triple therapy for eradication of H. pylori: A large multicenter, randomized trial","volume":"110","author":"Misiewicz JJ","year":"1996","journal-title":"Gastroenterol"},{"issue":"4","key":"e_1_2_5_18_2","first-page":"A226","article-title":"Highly effective, well tolerated one\u2010week triple therapy with omeprazole, clarithromycin and amoxicillin for Helicobacter pylori infection","volume":"110","author":"Peitz U","year":"1996","journal-title":"Gastroenterol"},{"issue":"4","key":"e_1_2_5_19_2","first-page":"A126","article-title":"Triple therapy of omeprazole + amoxicillin + clarithromycin is effective for the cure of Helicobacter pylori infection in gastric and duodenal ulcer patients","volume":"110","author":"Habu Y","journal-title":"Results of a randomized study involving"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/29.2.115"},{"key":"e_1_2_5_21_2","first-page":"1860","article-title":"Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double\u2010blind trial","volume":"88","author":"Peterson WL","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.9.1637"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1994.tb00313.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.35.3.323"},{"key":"e_1_2_5_25_2","first-page":"835","article-title":"Efficacy and optimum dose of omeprazole in a new 1\u2010week triple therapy regimen to eradicate Helicobacter pylori","volume":"7","author":"Moayyedi P","year":"1995","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Helicobacter"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1523-5378.1998.08021.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1523-5378.1998.08021.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1523-5378.1998.08021.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1523-5378.1998.08021.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T04:49:26Z","timestamp":1694407766000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1523-5378.1998.08021.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,3]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1998,3]]}},"alternative-id":["10.1046\/j.1523-5378.1998.08021.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1523-5378.1998.08021.x","archive":["Portico"],"relation":{},"ISSN":["1083-4389","1523-5378"],"issn-type":[{"value":"1083-4389","type":"print"},{"value":"1523-5378","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,3]]}}}